Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Profit After Tax (2016 - 2025)

KalVista Pharmaceuticals' Profit After Tax history spans 11 years, with the latest figure at -$52.2 million for Q2 2025.

  • On a quarterly basis, Profit After Tax fell 16.97% to -$52.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$179.6 million, a 41.8% decrease, with the full-year FY2025 number at -$183.4 million, down 44.85% from a year prior.
  • Profit After Tax hit -$52.2 million in Q2 2025 for KalVista Pharmaceuticals, down from -$42.3 million in the prior quarter.
  • Over the last five years, Profit After Tax for KALV hit a ceiling of -$10.0 million in Q1 2021 and a floor of -$52.2 million in Q2 2025.
  • Historically, Profit After Tax has averaged -$34.0 million across 4 years, with a median of -$34.7 million in 2024.
  • Biggest five-year swings in Profit After Tax: fell 8.15% in 2021 and later tumbled 59.75% in 2024.
  • Tracing KALV's Profit After Tax over 4 years: stood at -$10.0 million in 2021, then crashed by 175.18% to -$27.6 million in 2023, then plummeted by 52.87% to -$42.3 million in 2024, then fell by 23.56% to -$52.2 million in 2025.
  • Business Quant data shows Profit After Tax for KALV at -$52.2 million in Q2 2025, -$42.3 million in Q4 2024, and -$40.4 million in Q3 2024.